撰稿 | 郑诗蔚   责编 | 周叶斌近年来，靶向CD19的CAR T细胞疗法在治疗儿童和青少年复发或难治性急性淋巴细胞白血病（ALL）方面卓有成效，但约一半的患者在CAR ...

【导读】针对肿瘤特异性新抗原的免疫治疗具有潜力，但它们在肿瘤细胞上的超低表达，对T细胞治疗提出了挑战。在这项研究中，团队发现，嵌合抗原受体（CARs）在针对人类白细胞抗原（HLA）I类呈现的p53R175H新抗原时，其敏感性比T细胞受体（TCRs）低 ...

Construction of CAR or other engineered T cell receptors - Traditional and innovative CAR structural designs - Practical aspects of screening and manufacturing CAR therapies - Feasibility studies in ...

PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) is set to showcase groundbreaking advancements in its iPSC-derived ...

Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic ...

Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...

Driving at over 200 miles per hour in a barely legal street car while struggling to avoid busy ... upgrade the parts of vehicles. Players don't have to be a gearhead to appreciate the nuances ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.

1Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain. 2Navarra Institute for Health Research (IDISNA), Pamplona, Spain. 3Centro de Investigación Biomédica en Red de ...

The development of CAR-T cell therapy marks a major breakthrough in cancer treatment. These “living drugs” are T-cells genetically engineered to spread through the body, identify, and destroy cancer ...